Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million

Reuters03-19
Larimar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million
  • Larimar published a fourth-quarter and full-year 2025 financial results press release.
  • Q4 net loss widened 117% to USD 62.5 million, while R&D expense rose 122% to USD 59.37 million, driven mainly by higher nomlabofusp manufacturing costs tied to process performance qualification and commercialization scale-up.
  • For FY 2025, net loss increased 106% to USD 165.67 million and R&D expense rose 110% to USD 154.22 million, primarily reflecting higher nomlabofusp manufacturing costs and increased clinical, quality, and regulatory activity.
  • Cash, cash equivalents and marketable securities totaled USD 136.9 million at year-end, and pro forma cash, cash equivalents and marketable securities were USD 244.5 million following USD 107.6 million in net proceeds from a February 2026 public offering.
  • Nomlabofusp updates included FDA Breakthrough Therapy Designation, topline open-label data expected in Q2 2026, a planned BLA submission for accelerated approval in June 2026, and a projected cash runway into Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700PRIMZONEFULLFEED9674579) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment